Apoptosis in HCT116 Cell Lines Over Time: Analyzing Cell Number, Living Cells, and LC3 Activation

Jan 12, 2025

10 likes | 75 Views

Study on apoptosis in HCT116 cell lines (EV and MAPK14CA) over 28 days. Analysis includes cell number, living cells, and LC3 activation.

Share Presentation

Embed Code

raymond-kemp

Download Presentation

Apoptosis in HCT116 Cell Lines Over Time: Analyzing Cell Number, Living Cells, and LC3 Activation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

14 12 10 8 % APOPTOSIS HCT116-EV 4 6 HCT116-MAPK14CA 4 3 2 Cell number (106) 2 0 HCT116 EV HCT116 MAPK14 1 0 0 2 4 6 8 10 12 Days HCT116-EV 120 HCT116-MAPK14CA 100 HCT116 MAPK14CA 80 EV D7 D14 D21 60 % living cells LC3 Actin 40 20 0 D7 D14 D21 D28 Supplementary Figure 1 A B C D

Supplementary figure 1

Supplementary figure 1. Supplementary figure 2 . sNF96.2. ST88-14. T265-2C. NF90.8. Supplementary figure 3. NF90.8. sNF96.2. T265-2C. ST88-14. Supplementary figure 4. A. B. NF90.8. siRNA mTOR#13. siRNA mTOR#19. siRNA GFP. mTOR. GAPDH. ST88-14. siRNA mTOR#13.

220 views • 12 slides

Supplementary Figure 1

Supplementary Figure 1. MW/1000. pH. SJIA. POLY. Others. F. FI. F. KD. Q. Q. C3. AGP1. ACT. SAP. SAA. S100A8. S100A9. HP. CRP. C9. C4. APO-IV. APO-L1. AMBP. KLKB1. VDB. CFH. ATIII. A2M. ATIII. APO-E. APO-D. FGG FGB. TTR. GSN. APOA1. Figure 1. 12. 10. 8.

196 views • 7 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C. Supplementary Figure 2. Supplementary Figure 3. A. PHTX-14B Day 10. B. MDA-MB-231 Day 10. Supplementary Figure 4. Vehicle. MLN8237 20mg/kg QDx3/wk. Treatment Period. 2500. 2000. 1500. Average Tumor Volume (mm^3). 1000. 500. 0. 0. 10. 20.

266 views • 5 slides

Supplementary Figure 1

Supplementary Figure 1. 3. 2,5. 2. 1,5. 1. 0,5. 0. 6. 5. 4. 3. 2. 1. 0. A. WT with FSK+Gen. WT with FSK. lF508del with FSK+Gen. lF508del with FSK. ns. ns. ns. ns. Bicarbonate secretion ( normalized to the rate in FSK-treated F508del as 1). 10 min post peak response.

124 views • 2 slides

Supplementary Figure 1

Supplementary Figure 1. a. b. c. a continuous schedule for 35 consecutive days. an intermittent schedule. DNA vaccination (50 ug/mouse). DNA vaccination (50 ug/mouse). A20 Lymphoma. A20 Lymphoma. Day. Day. 1. 35. 0. 14. 28. 0. 14. 28. 42. 21. 18. 35. 42. 32. 7. 4.

112 views • 3 slides

Supplementary Figure 1

a. *. *. ns. 3. 2. RANK Arbitrary Score. 1. 0. b. RANK. 1 2 3 4 5 6 7 8 9 10 11. Metastasis lymph node. Primary tumor. Normal breast. Supplementary Figure 1. Prolactin. RANKL. RANKL. pERK1/2. pERK1/2. pAKT. ERK1/2. AKT. b -Actin. pSTAT5. STAT5.

187 views • 7 slides

Supplementary Figure 1

Supplementary Figure 1. HM466934. I. II. pre-A. A. B. C. D/E. Supplementary Figure 2. V. IV. HM466934. HM466934. VI. HM466934. Supplementary Figure 3. HM466935. CDUV. Supplementary Figure 4. 34. MRMBV. MRCV. TUAV. ORXV. ALEV.

184 views • 4 slides

Supplementary Figure 1

IgVH unmutated. IgVH mutated. Low-risk. Intermediate-risk. High-risk. P14 cluster. N6 cluster. ZAP-70. CD38. IgVH status. Supplementary Figure 1.

96 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. CEPH: CYP2C8 (40kb, chr10:96782845..96822844). MAF=0.05. B. Hap-B. Hap-E. Hap-F. Haplotypes above 2%. Hap-A. Hap-D. Hap-C1+C2. Hap-C3. 3´UTR. CYP2C8. Pr. A. JPT+HCB: Asian. YRI: African. Supplementary Figure 2. A. B. C. A. B. C. Hap D (*3). Hap B.

215 views • 3 slides

Supplementary Figure 1

A. B. D. C. E. CD20. CagA. Merge. DAPI. Supplementary Figure 1.

178 views • 2 slides

Supplementary Figure 1

Nephrin. Nephrin. Nephrin. Nephrin. Nephrin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. A. Merge. Merge. Merge. Merge. Merge. B. Podocin. Podocin. Podocin. Podocin. Podocin. Day 28. Control. Day 3. Day 15. Day 7. ADRN 11 mg/kg. Cont. Day3.

79 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. MIG (pMSCV-ires-GFP). I. GFP. LTR. LTR. MIG-PL2 (pMSCV-PLAGL2-ires-GFP). PL2. GFP. LTR. LTR. I. B. CBFb-MYH11 + HPs. GFP sort. Gene expression profile. Genes commonly deregulated in PL2+ cells. MIG-PL2 transduction. MIG transduction. GFP sort.

136 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C.

79 views • 1 slides

Supplementary Figure 1.

MgrA. MepR. Supplementary Figure 1.

84 views • 1 slides

Supplementary Figure 1

90. 85. 80. 75. 70. 65. 40. 44. 48. 52. 56. 90. 80. 70. 60. 50. 38. 40. 42. 44. 46. 48. 50. 52. 90. 80. 70. 60. 50. 40. 30. 25. 30. 35. 40. 45. 50. 55. Normal. r = 0.043. p = 0.678. Methylation Level of LINE1 (%). Background. r = 0.063. p = 0.559.

111 views • 3 slides

Supplementary Figure 1

Supplementary Figure 1. Nominal p-value =0.0 FDR q-value= 0.19. Nominal p-value =0.004 FDR q-value= 0.30. Nominal p-value =0.013 FDR q-value= 0.19. Nominal p-value =0.033 FDR q-value= 0.18. Nominal p-value = 0.007 FDR q-value= 0.18. Nominal p-value =0.075 FDR q-value= 0.19.

123 views • 5 slides

Supplementary Figure 1

Supplementary Figure 1. Venkatachalam et al. 2013. ab. a. ab. abc. c. 24 48 72 96 120. Hours after FB17 treatment. Supplementary Figure 2. Venkatachalam et al. 2013. At1g11610. At3g28360. At1g21240. At3g14460. At3g20190. UBQ1.

151 views • 4 slides

Supplementary Figure 1

Supplementary Figure 1. Expansion of MSCs in 20% oxygen vs 5% oxygen. Supplementary Figure 2. Expansion of Kaneka-filtered cells in Flasks (P4) and the Quantum (P2). Supplementary Figure 3. Adipogenesis. Osteogenesis. Chondrogenesis.

266 views • 8 slides

Supplementary Figure 1

83 views • 2 slides

Supplementary Figure 1

Supplementary Figure 1. ***. 120000. 100000. ***. 80000. 60000. Relative light units (RLU). 40000. 20000. 0. Dox. +. -. +. -. Line I. Line 2. rtTA. rtTA. A. MMTV- rtTA TET0-PELP1 Line 1. MMTV- rtTA TET0-PELP1 Line 2. B. TetO-PELP1. MMTV- rtTA. WT. + Dox. T7-PELP1.

108 views • 1 slides

Supplementary Figure 1

A. *. A average weight [g]. A average weight [g]. CR. CR. Control. Control. T ime of experiment [week s ]. T ime of experiment [week s ]. *p<0,05. B. Supplementary Figure 1.

80 views • 1 slides

Supplementary Figure 1.

88 views • 1 slides

More Related